PMID- 22581357
OWN - NLM
STAT- MEDLINE
DCOM- 20121019
LR  - 20240104
IS  - 1531-703X (Electronic)
IS  - 1040-8746 (Linking)
VI  - 24
IP  - 5
DP  - 2012 Sep
TI  - Molecular targets and targeted therapeutics in endometrial cancer.
PG  - 554-63
LID - 10.1097/CCO.0b013e328354e585 [doi]
AB  - PURPOSE OF REVIEW: Endometrial cancer is the most common gynaecological 
      malignancy in the western world. Two clinicopathological subtypes are recognized: 
      type I (endometrioid) and type II (nonendometrioid) carcinomas. This review 
      describes the molecular alterations in endometrial cancer and how this knowledge 
      is leading to the development of novel treatments in this area. RECENT FINDINGS: 
      Molecularly targeted agents have entered clinical trials in endometrial cancer. 
      So far, mechanistic target of rapamycin (mTOR) inhibitors and antiangiogenic 
      agents appear promising and are being pursued further in addition to other 
      targeted approaches. SUMMARY: The clinicopathological and molecular heterogeneity 
      of endometrial cancer needs to be taken into account in the design of future 
      clinical trials as well as the incorporation of robust biomarkers for the success 
      of therapeutic strategies in endometrial cancer.
FAU - Weigelt, Britta
AU  - Weigelt B
AD  - Cancer Research UK London Research Institute, London, UK.
FAU - Banerjee, Susana
AU  - Banerjee S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr Opin Oncol
JT  - Current opinion in oncology
JID - 9007265
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Angiogenesis Inhibitors/pharmacology/therapeutic use
MH  - Antineoplastic Agents/*pharmacology/therapeutic use
MH  - Endometrial Neoplasms/*drug therapy/genetics/metabolism
MH  - Female
MH  - Humans
MH  - Molecular Targeted Therapy/*methods
EDAT- 2012/05/15 06:00
MHDA- 2012/10/20 06:00
CRDT- 2012/05/15 06:00
PHST- 2012/05/15 06:00 [entrez]
PHST- 2012/05/15 06:00 [pubmed]
PHST- 2012/10/20 06:00 [medline]
AID - 10.1097/CCO.0b013e328354e585 [doi]
PST - ppublish
SO  - Curr Opin Oncol. 2012 Sep;24(5):554-63. doi: 10.1097/CCO.0b013e328354e585.